Here’s What Makes Pfizer (PFE) the Best Stock in Carillon Clarivest Capital Appreciation Fund’s Portfolio

Carillon Tower Advisers, an investment management company, released its “Carillon Clarivest Capital Appreciation Fund” second quarter 2022 investor letter. A copy of the same can be downloaded here. Global equities markets were facing significant declines in the first half of 2022 due to concerns like the Russia/Ukraine war, surging inflation, COVID-19, and central-bank tightening. At the end of the second quarter, the portfolio was most underweight in consumer discretionary and industrials sectors and most overweight in the information technology and healthcare sectors. But all sectors in the Russell 1000 Index were negative. However, the stock selection and sector allocation contributed positively to the fund’s performance. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Carillon Tower Advisers discussed stocks like Pfizer Inc. (NYSE:PFE) in the second quarter 2022 investor letter. Headquartered in New York, New York, Pfizer Inc. (NYSE:PFE) is a biopharmaceutical company. On October 5, 2022, Pfizer Inc. (NYSE:PFE) stock closed at $44.12 per share. One-month return of Pfizer Inc. (NYSE:PFE) was -4.36% and its shares gained 5.00% of their value over the last 52 weeks. Pfizer Inc. (NYSE:PFE) has a market capitalization of $247.617 billion.

Here is what Carillon Tower Advisers specifically said about Pfizer Inc. (NYSE:PFE) in its Q2 2022 investor letter:

Pfizer Inc. (NYSE:PFE) is a research-based global biopharmaceutical company. The United States agreed to pay Pfizer and its vaccine partner more than $3 billion in a deal for their messenger RNA shots against COVID-19. Additionally, the U.S. Food and Drug Administration authorized the company’s COVID vaccine for children aged 5 to 11.”

Pfizer Inc. (NYSE:PFE) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 70 hedge fund portfolios held Pfizer Inc. (NYSE:PFE) at the end of the second quarter which was 79 in the previous quarter.

We discussed Pfizer Inc. (NYSE:PFE) in another article and shared the list of COVID stocks to invest in. In addition, please check out our hedge fund investor letters Q2 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.